International recommendations for the prevention and treatment of venous thromboembolism associated with cancer

Clinical Drug Investigation

Volumn 29, Issue 10, 2009, Pages 625-633

  Khosravi Shahi, Parham ^a   Pérez Manga, Gumersindo ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; APREPITANT; ARGATROBAN; BEMIPARIN; BEVACIZUMAB; DABIGATRAN ETEXILATE; DALTEPARIN; DEXAMETHASONE; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; LENALIDOMIDE; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PHENYTOIN; PLACEBO; THALIDOMIDE; THROMBIN INHIBITOR; TINZAPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; NEOPLASM; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; THROMBOGENICITY; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DRUG UTILIZATION; GUIDELINES AS TOPIC; HUMANS; NEOPLASMS; THROMBOEMBOLISM;

EID: 69549083075     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11315310-000000000-00000     Document Type: Review

References (63)

1. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632-634 (Pubitemid 46680709)
2. Stein PD, Beemath A, Meyers FA, et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006; 119: 60-68 (Pubitemid 43117468)
3. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24: 484-490 (Pubitemid 46630468)
4. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-815 (Pubitemid 30165241)
5. Kroger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006; 17: 297-303 (Pubitemid 43160121)
6. Sousou T, Khorana AA. New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol 2009; 29: 316-320
7. Khorana AA, Francis CW, Culakova E, et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104: 2822-2829 (Pubitemid 41798294)
8. Blom JW, Vanderschoot JP, Oostindier MJ, et al. Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 4: 529-535
9. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614-1615
10. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277-2285
11. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006; 243: 89-95 (Pubitemid 43054059)
12. Gallus AS. Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost 1997; 78: 126-132 (Pubitemid 27289229)
13. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488 (Pubitemid 35303914)
14. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004; 164: 1653-1661 (Pubitemid 39037944)
15. Leonardi MJ, McGory ML, Ko CY. A systematic review of deep venous thrombosis prophylaxis in cancer patients: implications for improving quality. Ann Surg Oncol 2007; 14: 929-936
16. van Doormaal FF, Buller HR, Middeldorp S. Development in anticoagulant therapy. Crit Rev Oncol Hematol 2008; 66: 145-154
17. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolismin stage IV breast cancer. Lancet 1994; 343: 886-889 (Pubitemid 24113632)
18. Smorenburg SM, Vink R, Otten HM, et al. The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 2001; 86: 1586-1587 (Pubitemid 34007540)
19. Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 269-277 (Pubitemid 26111623)
20. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505 (Pubitemid 350232226)
21. Agencia Española del Medicamento (Spanish Drug Agency) [online]. Available from URL: http://www.agemed.es/www.agemed.es [Accessed 2009 Mar 10]
22. Enoxaparin sodium injection (Lovenox®) for subcutaneous and intravenous use: prescribing information, 2007 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/022138,020164s075lbl. pdf [Accessed 2007 May 16]
23. Tinzaparin sodium injection [Innohep]: prescribing information, 2008 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2008/020484s011lbl.pdf [Accessed 2009 May 21]
24. Cheer SM, Dunn CJ, Foster R. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease. Drugs 2004; 64: 1479-1502 (Pubitemid 38980459)
25. Dalteparin (Fragmin): prescribing information, 2009 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/ 020287s035lbl.pdf [Accessed 2009 May 15]
26. Dunn CJ, Jarvis B. Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease. Drugs 2000; 60: 203-237 (Pubitemid 30601316)
27. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.N Engl J Med 2003; 349: 146-153
28. Fraxiparine, Fraxiparine Forte (nadroparin calcium) product monograph (Canada). GlaxoSmithKline, 2008 [online]. Available from URL: http://www.gsk.ca/english/docs-pdf/Fraxiparine-Forte-PM-20080916-EN.pdf [Accessed 2009 Jul 20]
29. Agnelli G, Gussoni G, Bianchini C, et al. A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: the PROTECHT study [abstract]. Blood 2008; 112: 6
30. Martinez-Gonzalez J, Vila L, Rodriguez C. Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism. Expert Rev Cardiovasc Ther 2008; 6: 793-802
31. Chapman TM, Goa KL. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis. Drugs 2003; 63: 2357-2377
32. Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY) [NCT00324558], 2009 [online]. Available from URL: http://clinicaltrials.gov/ct2/ show/NCT00324558 [Accessed 2009 May 21]
33. CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation) [ClinicalTrials.gov identifier NCT00219973], US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/ [Accessed 2009 May 21]
34. Gomez-Outes A, Rocha E, Martinez-Gonzalez J, et al. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis. Pharmacoeconomics 2006; 24: 81-92 (Pubitemid 43197233)
35. Schadlich PK, Kentsch M, Weber M, et al. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany. Pharmacoeconomics 2006; 24: 571-591 (Pubitemid 43886268)
36. Heerey A, Suri S. Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery. Pharmacoeconomics 2005; 23: 927-944 (Pubitemid 41317426)
37. Caro JJ, Getsios D, Caro I, et al. Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis. Pharmacoeconomics 2002; 20: 593-602 (Pubitemid 34898995)
38. Mousa SA. Role of current and emerging antithrombotics in thrombosis and cancer. Drugs Today (Barc) 2006; 42: 331-350 (Pubitemid 43980718)
39. Fondaparinux sodium (Arixtra): prescribing information, 2009 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/ 021345s010lbl.pdf [Accessed 2009 May 21]
40. Dhillon S, Plosker GL. Fondaparinux: use in thromboprophylaxis of acute medical patients. Drugs Aging 2008; 25: 81-88
41. Robinson DM, Wellington K. Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism. Am J Cardiovasc Drugs 2005; 5: 335-346 (Pubitemid 41306472)
42. Wong CK, White HD. Direct antithrombins: mechanisms, trials, and role in contemporary interventional medicine. Am J Cardiovasc Drugs 2007; 7: 249-257
43. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775 (Pubitemid 351930851)
44. Mandala M, Falanga A, Piccioli A, et al. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 2006; 59: 194-204 (Pubitemid 44403960)
45. Wagman LD, Baird MF, Bennett CL, et al. Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2008; 6: 716-753
46. Khorana AA. The NCCN clinical practice guidelines on venous thromboembolic disease: strategies for improving VTE prophylaxis in hospitalized cancer patients. Oncologist 2007; 12: 1361-1370
47. Mandala M, Falanga A, Roila F. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 2008; 19 Suppl. 2: ii126-7
48. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793-800
49. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-879 (Pubitemid 39096017)
50. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332: 325-329
51. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83: 14-19 (Pubitemid 30045469)
52. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997; 84: 1099-1103
53. Bergqvist D, Burmark US, Flordal PA, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995; 82: 496-501
54. McLeod RS, Geerts WH, Sniderman KW, et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian Colorectal DVT Prophylaxis Trial. A randomized, double-blind trial. Ann Surg 2001; 233: 438-444
55. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975-980 (Pubitemid 34983247)
56. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006; 4: 2384-2390 (Pubitemid 44575433)
57. Kuderer NM, Khorana AA, Lyman GH, et al. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007; 110: 1149-1161
58. Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Med 2002; 113: 636-642 (Pubitemid 36015799)
59. Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12: 389-396 (Pubitemid 44359237)
60. Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-1072
61. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-1735 (Pubitemid 34894802)
62. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371: 387-394
63. Mandala M, Barni S, Floriani I, et al. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. Eur J Cancer 2009; 45: 65-73